Keryx Biopharmaceuticals (NASDAQ:KERX) has climbed 2.02% in the past week and advanced 5.4% in the last 4 weeks. In the past week, the company has outperformed the S&P 500 by 3.25% and the outperformance has advanced to 4.44% for the last 4 weeks period.
Keryx Biopharmaceuticals (NASDAQ:KERX): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $6.03 and $5.95 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $6.24. The buying momentum continued till the end and the stock did not give up its gains. It closed at $6.05, notching a gain of 0.83% for the day. The total traded volume was 1,744,876 . The stock had closed at $6.00 on the previous day.
The company shares have dropped -41.09% from its 1 Year high price. On Jul 17, 2015, the shares registered one year high at $10.51 and the one year low was seen on Jan 20, 2016. The 50-Day Moving Average price is $5.77 and the 200 Day Moving Average price is recorded at $4.75.
On the companys insider trading activities, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the director officer (President and CEO) of Keryx Biopharmaceuticals Inc, Madison Greg had sold 1,873 shares worth of $10,152 in a transaction dated May 9, 2016. In this transaction, 1,873 shares were sold at $5.42 per share.
Many analysts have stated their opinion on the company shares. Maxim Group maintains its view on Keryx Biopharmaceuticals (NASDAQ:KERX) according to the research report released by the firm to its investors. The shares have now been rated Buy by the stock experts at the ratings house. Maxim Group raises the price target from $5 per share to $7 per share on Keryx Biopharmaceuticals . The rating by the firm was issued on March 29, 2016. Currently the company Insiders own 3.08% of Keryx Biopharmaceuticals shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -2.04% . Institutional Investors own 62.06% of Keryx Biopharmaceuticals shares. During last six month period, the net percent change held by insiders has seen a change of 69.09%.
Keryx Biopharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development of products for the treatment of renal diseases. Its lead product Auryxia (ferric citrate), an oral, absorbable iron-based compound, received marketing approval from the United States Food and Drug Administration (FDA), for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis. The approval of Auryxia was based on data from its Phase III registration program, in which Auryxia effectively reduced serum phosphorus levels to well within the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines range of 3.5 to 5.5 mg/dL. In addition to the effects on serum phosphorus levels, Auryxias pharmacodynamic properties resulted in increased ferritin, iron and transferrin saturation (TSAT).